Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
NANOBIOTIX ANNOUNCES NEW ORGANIZATIONAL STRUCTURE AS THE COMPANY ENTERS ITS NEXT STAGE AFTER FIRST EUROPEAN MARKET APPROVAL
- Recently appointed Chief Medical Officer (CMO) Edwina Baskin-Bey, M.D., will join the Executive Board
- Anne-Juliette Hermant, M.A., will be appointed Chief People Officer (CPO) and will join the Executive Board
- Former CMO Elsa Borghi, M.D., will lead innovation and drug discovery for the company while leaving the Executive Board to focus on her new responsibilities
- Chief Business Officer (CBO) Bernd Muehlenweg, Ph.D., will step down from the Executive Board and exit the company
- Patrick Tricoli, Pharm.D. M.B.A., will remain CEO of Nanobiotix Corp, the company’s U.S. affiliate, and also take on a new role as the Global Head of Business Development
- Brandon Owens will be appointed Vice President (VP) of Strategic Marketing and Corporate Communications
“As we enter our next stage as a company after receiving our first European market approval for Hensify® (NBTXR3) in Soft Tissue Sarcoma, we feel it is necessary to ensure we are optimally structured for continued success. As such, we are delighted to welcome our newcomers and congratulate those stepping into new roles. I also want to personally thank Dr. Bernd Muehlenweg, without whom we never would have achieved the business successes we have realized to this point. We are in a new era at Nanobiotix and I am confident these changes will serve to accelerate our growth.” – Laurent Levy, CEO of Nanobiotix
Paris, France and Cambridge, Massachusetts, USA, July 1, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced organizational changes to align with strategic priorities post European market approval for Hensify® (NBTXR3). The changes aim to reinforce necessary competencies as strategic priorities evolve, and to help accelerate the company’s longstanding mission to significantly improve outcomes for patients.
New C-level Appointments and Executive Board Members
Recently appointed CMO Dr. Edwina Baskin-Bey will join the Executive Board. Ms. Anne-Juliette Hermant will be appointed CPO and will join the Executive Board as well.
C-level and Executive Board Departures
As mentioned in a previous press release, former CMO Dr. Elsa Borghi will leave the Executive Board to take on a new function leading innovation and drug discovery. CBO Dr. Bernd Muehlenweg will step down from the Executive Board and exit the company.
New Management Appointments and Responsibilities
Dr. Patrick Tricoli will remain CEO of Nanobiotix Corp, the company’s U.S. affiliate, while also taking on a new role as Global Head of Business Development. Mr. Brandon Owens will join Nanobiotix as its newly appointed VP of Strategic Marketing and Corporate Communications.
Newcomer Biographical Details
Ms. Anne-Juliette Hermant
Anne-Juliette Hermant brings over 14 years of experience in HR, talent management and development, acquired across various entities at AXA. Ms. Hermant worked at AXA Partners for 3 years as Global Head of Talent, Development, Culture and Corporate Responsibility.
Before AXA Partners, Anne-Juliette served as Chief Learning Officer of the AXA Group and was the Founder and Head of the AXA Research Fund, a €100 million fund created by the AXA Group to support frontier science in all fields related to an understanding of the risks faced by human society.
Anne-Juliette was born in Strasbourg, France and grew up between the French overseas territories of Guyane, Martinique and Guadeloupe. She relocated to Lyon and then to Paris to pursue her studies and has remained in the city throughout her career.
Anne-Juliette graduated from the Ecole Normale Supérieure and studied Politics at Sciences Po Paris. She holds an Agregation and an M.A. in French literature.
Mr. Brandon Owens
Brandon Owens is a career communications professional that most recently functioned as a Vice President on the Citigroup account at Publicis New York. Mr. Owens was responsible for Citi’s global reputation management communications and focused on integrated campaigns meant to influence policy decisions relevant to banking in over 100 different countries.
Prior to Publicis, Brandon worked at agencies in both New York and Chicago, leading accounts including Procter and Gamble, Verizon Wireless, and Diageo.
Originally, Brandon comes from the Washington, D.C. area of the United States. After starting his career in sales for a small software firm in Baltimore, Maryland, he moved to Chicago to begin his career in advertising. From there he moved to New York City where he presently resides.
Brandon received his B.S. in Business from the Robert H. Smith School of Business at the University of Maryland.
About NANOBIOTIX: www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.
Investor Relations Department
France – Springbok Consultants
United States – RooneyPartners
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorité des Marchés Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.